An Open-label, Multicenter Study of LY4050784, a Selective SMARCA2/BRM Inhibitor, in Advanced Solid Tumor Malignancies With SMARCA4/BRG1 Alterations
Latest Information Update: 01 Jun 2025
At a glance
- Drugs FHD 909 (Primary)
- Indications Non-small cell lung cancer; Solid tumours
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Eli Lilly and Company
Most Recent Events
- 23 May 2025 Planned number of patients changed from 160 to 340.
- 23 May 2025 Planned End Date changed from 1 Oct 2027 to 1 May 2028.
- 30 Apr 2025 Trial design presented at the 116th Annual Meeting of the American Association for Cancer Research